{"id":"W2048514971","doi":"10.1097/qad.0b013e3283612419","title":"Dolutegravir in antiretroviral-naive adults with HIV-1","year":2013,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Tolerability; Dolutegravir; Emtricitabine; Efavirenz; Medicine; Abacavir; Regimen; Adverse effect; Lamivudine; Internal medicine; Clinical endpoint; Viral load; Integrase inhibitor; Gastroenterology; Human immunodeficiency virus (HIV); Pharmacology; Randomized controlled trial; Virology; Antiretroviral therapy; Virus; Hepatitis B virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009047911,0.0002837527,0.0006830411,0.0001108686,0.0001894824,0.0003271202,0.0002206324,0.0004913501,0.001670102],"category_scores_gemma":[0.0009181739,0.0001766159,0.0003777324,0.0001581431,0.0001693835,0.0003387443,0.0001855441,0.0006525207,0.0002989085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002972273,"about_ca_system_score_gemma":0.0004697207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006251152,"about_ca_topic_score_gemma":0.001840743,"domain_scores_codex":[0.9996842,0.000132873,0.00003385726,0.00004694594,0.00005809502,0.00004407354],"domain_scores_gemma":[0.9997535,0.00005848497,0.00006388665,0.00001031012,0.00002549931,0.00008829677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4497336,0.02417487,0.1564412,0.002079776,0.00104349,0.0006544055,0.000725283,0.001116057,0.03356653,0.000232747,0.003286608,0.3269455],"study_design_scores_gemma":[0.1960965,0.5017202,0.2796163,0.0003414261,0.001115621,0.001185382,0.000401175,0.001863488,0.005444854,0.0003136808,0.01186136,0.00003998139],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952186,0.003037217,0.00008368431,0.0002033152,0.00003895733,0.0002524795,0.0002863146,0.00001557264,0.0008638534],"genre_scores_gemma":[0.9960968,0.001534473,0.000418798,0.000468883,0.00007348342,0.000221047,0.0003291245,0.000003394095,0.0008540086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001670102,"threshold_uncertainty_score":0.005587041,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006139543352020244,"score_gpt":0.2205028907488554,"score_spread":0.2143633473968352,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}